Faber Report: Top Bristol-Myers shareholder doesn't back Celgene deal

CNBC's David Faber reports on Bristol-Myers' top shareholder Wellington Management putting out a statement saying they do not back the biopharmaceutical company's plans to purchase competitior Celgene.
05:50
Thu, Feb 28 20199:40 AM EST